Literature DB >> 14677188

Serum cytokine profiles in patients with adult onset Still's disease.

Jeong-Hee Choi1, Chang-Hee Suh, Young-Mok Lee, Yu-Jin Suh, Soo-Keol Lee, Sun-Sin Kim, Dong-Ho Nahm, Hae-Sim Park.   

Abstract

OBJECTIVE: Adult onset Still's disease (AOSD) is a systemic inflammatory disorder characterized by fever, arthritis, and rash. Although the pathogenesis is not known, immunologically mediated inflammation occurs in active AOSD. To evaluate the pathogenesis and disease activity of AOSD, we measured serial serum concentrations of several cytokines in patients with active and inactive disease.
METHODS: Seventeen patients diagnosed as having AOSD were enrolled. We analyzed clinical and laboratory findings retrospectively. Serial serum samples were obtained from 14 patients with active and inactive AOSD. Interleukin 18 (IL-18), soluble IL-2 receptor (sIL-2R), IL-6, interferon-g (IFN-g), and IL-8 were determined by ELISA.
RESULTS: Serum levels of IL-18, IFN-g, and IL-8 were significantly higher in patients with AOSD than in healthy controls (p < 0.01), but there were no significant differences between patients with active and inactive AOSD. Serum sIL-2R levels tended to be higher in the active state than in healthy controls, but there was no statistically significant difference between the 2 groups. Serum sIL-2R levels decreased significantly with antiinflammatory therapy (p < 0.05). Serum IL-18 and sIL-2R levels correlated significantly with serum ferritin levels in the active AOSD group (p < 0.05).
CONCLUSION: Overproduction of IL-18 may contribute to the pathogenic mechanism of AOSD, and serum sIL-2R levels may be used as a marker for monitoring disease activity in AOSD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677188

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  56 in total

1.  Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.

Authors:  Der-Yuan Chen; Joung-Liang Lan; Fang-Ju Lin; Tsu-Yi Hsieh
Journal:  Clin Rheumatol       Date:  2006-09-14       Impact factor: 2.980

2.  Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure.

Authors:  Deng-Ho Yang; Deh-Ming Chang; Jenn-Haung Lai; San-Yuan Kuo; Tsung-Yun Ho; Kang-Min Lin; Chen-Hung Chen
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

Review 3.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

4.  Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.

Authors:  Paola Cipriani; Piero Ruscitti; Francesco Carubbi; Ilenia Pantano; Vasiliki Liakouli; Onorina Berardicurti; Roberto Giacomelli
Journal:  Clin Rheumatol       Date:  2013-09-05       Impact factor: 2.980

Review 5.  Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Fabio Martinon; Alexandre Belot; Thomas Henry; Pascal Sève
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

6.  Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic values.

Authors:  Toshiyuki Yamamoto
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

7.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

8.  The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

Authors:  Kuo-Tung Tang; Chia-Wei Hsieh; Hsin-Hua Chen; Yi-Ming Chen; Shih-Hsin Chang; Po-Hao Huang; Joung-Liang Lan; Der-Yuan Chen
Journal:  Clin Rheumatol       Date:  2021-09-17       Impact factor: 2.980

9.  Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis.

Authors:  Jeffrey H Ruth; Christy C Park; M Asif Amin; Charles Lesch; Hubert Marotte; Shiva Shahrara; Alisa E Koch
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

10.  Fulminant hemophagocytic syndrome with a high interferon gamma level diagnosed as macrophage activation syndrome.

Authors:  Tsuyoshi Muta; Yujiro Yamano
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.